A New Protocol for an Established Injectable 

babyGLOW™ uses one 3ml syringe of Redensity 1 across eight anatomically selected injection points on each side of the face. Four landmark lines guide product placement within the immediate subdermal layer, supporting controlled and homogeneous diffusion across the treatment area. 

Rather than relying on multiple superficial injections, the protocol uses Redensity 1’s high fluidity to distribute the product more evenly. This is intended to create a smooth, global effect while reducing the risk of the visible papules often associated with more superficial skin booster techniques.  

Two treatment pathways support different patient objectives: skin beautification and skin rejuvenation. This gives clinics a framework that can be adapted according to the patient’s age, skin condition and treatment goals following an appropriate clinical assessment. 

Why the Timing Matters 

Demand continues to move towards treatments that enhance skin quality without materially changing facial shape or requiring significant recovery time. Patients increasingly want results that look fresh rather than visibly “done”, particularly when planning treatment around work, travel or social events. 

babyGLOW™ sits directly within that shift. It is positioned for patients concerned with dullness, dehydration, uneven texture and early signs of ageing, rather than those seeking structural correction or substantial volume replacement. 

Preliminary real-world evidence involving nearly 80 women found that 98% reported an immediate visible glow and natural-looking results, while 93% were satisfied after completing the protocol. According to Teoxane, 98% also felt no downtime was required. The evaluation assessed both beautification and rejuvenation treatment courses across several European countries and was presented at IMCAS 2026.  

A Practical Addition to Clinic Menus 

For clinics, the commercial relevance lies in standardisation. A recognisable protocol with defined mapping and separate treatment pathways can make skin booster consultations easier to structure, support consistent delivery between practitioners and provide a clearer proposition for patients. 

Its course-based format also creates opportunities for planned treatment programmes and maintenance appointments, rather than positioning Redensity 1 solely as an occasional standalone treatment. The limited number of injection points, minimal treatment time and low-downtime positioning may also make it easier to integrate alongside existing facial rejuvenation services. 

Importantly, babyGLOW™ does not require clinics already using Redensity 1 to introduce an unfamiliar injectable. It provides a new technique and patient-facing treatment concept built around an established product.